SECURE-AD COVID-19 atopic eczema study (completed)

The SECURE-AD COVID-19 study was launched to investigate how COVID-19 affected people with atopic dermatitis. At that time, it was not known how the COVID-19 pandemic impacted patients with atopic dermatitis or what effect systemic medications had on COVID-19 outcomes. This register helped provide a better understanding of the effect COVID-19 had and, through this, helped improve patient care.